Piramal Pharma Ltd management interview: Piramal Pharma Raises FY27 Growth Guidance To 18-20%: What's Driving The Bullish Outlook? | ET Now
ET Now, 2026-10-28. Video: https://www.youtube.com/watch?v=G_4s2UUL1jc
- Growth guidance: Piramal Pharma grew 23% in the first half and is confident in its raised full-year growth guidance of 18 to 20%, citing good visibility on orders and forecasts. Growth was broad-based: complex hospital generics grew 24% and consumer health grew 14%.
- EBITDA outlook: Management expects significant improvement in EBITDA and PAT. More orders and revenue in the largely fixed-cost CDMO business should bring operational leverage, alongside efforts to improve operations and manage costs.
- Phase 3 pipeline: The expanded Phase 3 pipeline is expected to become commercial within the next 1 to 3 years, though not necessarily in FY28. It signals new on-patent business and supports the plan to expand commercial on-patent and differentiated businesses.
- Consumer health: The business is single-digit profitable and margin dilutive, but management is comfortable with it as a fast-growing, India-based business. Plans include fewer, bigger product launches and expanded distribution; it expects profitability to get closer to double digits by 2030.
- Operations and outlook: Management cited 7 observations at the Morpeth facility, mostly related to people and process, and expects to close them out soon. It described quarterly business as lumpy and said its focus is balancing growth across quarters and setting up next year well; further FY28 guidance will come later.